Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis.
Marco BelloneLorenzo PradelliStefano MolicaAdele Emanuela De FrancescoDaniela GhislieriEmanuele GuardalbenAntonietta CaputoPublished in: ClinicoEconomics and outcomes research : CEOR (2021)
O-chemo has superior clinical efficacy compared to rituximab, and should be considered a cost-effective option in first-line treatment of patients with advanced FL at intermediate or high risk in Italy. Incremental cost-effectiveness ratios are below the threshold considered affordable by developed countries.